本帖最后由 老马 于 2012-1-13 21:20 编辑
+ n6 [3 | r2 [" B, R3 }& a) v) h
爱必妥和阿瓦斯丁的比较
- {' w/ O5 O" M' z7 U5 y+ `: u
8 _$ ?+ F' L% H0 l$ q9 q" N
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
4 ]6 L/ ?- M( C$ K# ^& ^3 \
$ w G3 d" }, X+ ~: Z. Q" p
( Q: {1 r$ \5 a
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/' P4 F1 e9 S2 M$ x
==================================================
1 X8 g; \5 a) Q% ?1 KOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
; W3 d& r- J9 F! q# b9 aPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
3 ]) m, {! X) Q( u5 ~6 HResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.. v$ N3 p6 T# E7 r0 h3 R' y& x
|